Kala Pharmaceuticals Inc (KALA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $89,480
Last updated: Nov 17, 2026 at 4:10 PM ET
Kala Pharmaceuticals Inc (KALA) Statistics
Kala Pharmaceuticals (KALA) has a market cap of $89,480. It holds $229.00K more cash than debt, 255.92% of its market cap. Revenue fell 100.00% over the last 12 months from the 12 months before.
Total Valuation
| Market Cap | $89,480 |
|---|---|
| Latest price (Nov 17, 2026) | $3.43 |
Key Dates
The next earnings report is expected on Nov 17, 2026, covering the quarter ending Sep 30, 2026.
| Next Earnings Date | Nov 17, 2026 (expected) |
|---|---|
| Last Earnings Date | Aug 19, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is down 99.68% over 52 weeks and trades 63.86% below its 50-day average.
| Beta (1Y) | 2.92 |
|---|---|
| 52-Week Change | -99.68% |
| 1-Month Change | -40.64% |
| 3-Month Change | -87.30% |
| 6-Month Change | -95.48% |
| 5-Year Change | -100.00% |
| Total Return (1Y) | -99.68% |
| Total Return (3Y CAGR) | -92.51% |
| Total Return (5Y CAGR) | -88.05% |
| Return vs SPY (1Y) | -111.23% |
| Max Drawdown (1Y) | -99.83% |
| Max Drawdown (3Y) | -99.99% |
| Sharpe Ratio (1Y) | -4.20 |
| Correlation with SPY (1Y) | 0.29 |
| 50-Day Average | $9.49 |
| 200-Day Average | $151.61 |
| 52-Week Range | $3.44 to $2,865.00 |
| RSI (14 Days) | 22.3 |
| Average Volume (20 Days) | 202.64K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.88x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 6.88x |
|---|---|
| Quick Ratio | 6.88x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -111.46% and return on assets is -95.26% over the last 12 months.
| Return on Equity (ROE) | -111.46% |
|---|---|
| Return on Assets (ROA) | -95.26% |
Scores
KALA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Operating Income | -$20.99M |
| Pretax Income | -$10.08M |
| Net Income | -$10.08M |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 85.44% of the $10.58M in total assets.
| Cash and Equivalents | $229.00K |
|---|---|
| Total Debt | $0 |
| Net Cash | $229.00K |
| Net Cash Per Share | $92.64 |
| Working Capital | $9.04M |
| Shareholder Equity | $9.04M |
| Book Value Per Share | $3,658.63 |
| Total Assets | $10.58M |
| Total Liabilities | $1.54M |
Balance sheet as of Jun 30, 2026.
Cash Flow
| Operating Cash Flow | -$19.86M |
|---|---|
| FCF Per Share | -$1.03 |
Trailing 12 months through Jun 30, 2026.
Dividends and Yields
KALA does not pay a dividend.
| Buyback Yield | -108434.57% |
|---|---|
| Shareholder Yield | -108434.57% |
Stock Splits
The last split was a 1-for-30 reverse split on Nov 16, 2026.
| Last Split Date | Nov 16, 2026 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:30 |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About KALA
What is KALA's market cap?
Kala Pharmaceuticals has a market cap of $89,480.
How many shares of KALA are outstanding?
Kala Pharmaceuticals has 2.47K shares outstanding.
Does KALA pay a dividend?
No. Kala Pharmaceuticals does not pay a dividend.
How much debt does KALA have?
Kala Pharmaceuticals has $0 of total debt and $229.00K of cash and equivalents, a net cash position of $229.00K.
KALA pages: Overview, Charting, Earnings, Financials, Statistics, Competitors